Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have received a consensus rating of “Moderate Buy” from the seventeen ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (NYSE: PFE). The ...

The disposal represents Pfizer's exit from its investment in Haleon, which originated from a JV formed with GSK in 2019.

Pfizer stock has delivered its long-term shareholders a dividend that has grown for 16 consecutive years. The pace of those ...

Pfizer (NYSE:PFE – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Guggenheim in a research ...

Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's ...

Pfizer reportedly offered about 618 million shares through a placement with investors, according to a Wednesday statement.

Haleon was a joint venture between Pfizer and GSK before being listed in London as a separate company in 2022. GSK sold its remaining 4.2% holding in Haleon in May last year. Comments and questions to ...

Pfizer Inc. (PFE) agreed to sell its remaining stake worth $3.3 billion in Haleon PLC (HLN), marking its exit from the UK-based consumer ...